Stock screenerAll disclosures →
EDGAR →
TCRX
Conviction 20HealthcareScan · Fri, Jun 26, 2026Bullish marubozu
TCRX$0.9634+14.69%
ResistanceSupportVol 14Vol MA14 843.74K
Mar 27Apr 15May 4May 20Jun 9Jun 26
Price0.9634
Change+14.69%
Gap+0.49%
Rel volume9.12×
Avg volume707.97K
Avg $ vol661.78K
SMA 200.9423
SMA 501.07
SMA 2001.24
Price vs 50-10.19%
Price vs 200-22.46%
MA stackbearish
50/200 cross—
Supertrenddown · 1.10
RSI (14)50
MACD hist0.00
MACD crossbull · 0d
Stoch %K / %D68 / 31
ADX (14)22
+DI / −DI14 / 20
RSI divergence—
MACD divergence—
ATR %+8.42%
ADR %8.11%
52w high2.52
52w low0.8400
From 52w high-61.77%
Above 52w low+14.69%
New 52w highNo
SqueezeOn · 1d
Bollinger width25.26%
%B0.59
Donchian pos50.31%
Donchian high1.10
Donchian low0.8251
AVWAP (52w high)1.14
vs AVWAP high-15.51%
AVWAP (52w low)0.9139
vs AVWAP low+5.42%
OBV trendFlat
Chaikin MF (20)0.03
Today vs 20d9.12×
Avg vol (14d)843.74K
Avg vol (20d)707.97K
Avg $ vol (20d)661.78K
Market cap—
RS 3m (vs SPY)-31.03%
RS 6m (vs SPY)-13.98%
RS line new highNo
Trend template0/8
Technical rank23.7
1 week+4.72%
1 month-9.96%
3 months-6.47%
6 months+5.79%
1 year-37.44%
YTD-5.55%
P/E-0.16
P/B0.21
P/S1.95
P/FCF-0.14
EPS-1.00
Div yield—
ROE-133.89%
ROA-64.24%
Debt/Eq0.44
Current6.65
EV/EBITDA0.49
Gross margin—
Net margin—
Rev growth266.65%
EPS growth-1.78%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value-64.93M
Revenue982K
Net income-28.67M
Gross profit—
Free cash flow-139.73M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out61.07M
Employees142
ListedFri, Jul 16, 2021
Free float—
Float %—
Short interest—
Days to cover—
Short volume—
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction20 / 100
Pattern quality—
Tech rank23.7 / 100
Group rank50 / 100
Status lane—
Setup direction—
Pattern family
Resistance—
Support—
Days since event—
Candle confirmBullish marubozu
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in TCRX
No recent disclosed trades by Congress in TCRX. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in TCRX · 10 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
BAKER FELIX Director · Non- Qualified Stock Option (right to buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
Klencke Barbara Director · Stock Option (Right to Buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
Nicholson Garry A Director · Stock Option (Right to Buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
Dorton Katina Director · Stock Option (Right to Buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
BAKER BROS. ADVISORS LP Director · Non- Qualified Stock Option (right to buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
Baker Brothers Life Sciences LP Director · Non- Qualified Stock Option (right to buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
667, L.P. Director · Non- Qualified Stock Option (right to buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
BAKER JULIAN Director · Non- Qualified Stock Option (right to buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
Baker Bros. Advisors (GP) LLC Director · Non- Qualified Stock Option (right to buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
Woods Keith Director · Stock Option (Right to Buy) · 2026-05-20 | Grant | 67K | $0 | 2026-05-20 | 2026-05-22 |
SEC filings
EDGAR filings in TCRX · 1 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.